SB 239063
SIGMA/S0569 - >98% (HPLC)
Synonym: trans-
CAS Number: 193551-21-2
Empirical Formula (Hill Notation): C20H21N4O2F
Molecular Weight: 368.40
MDL Number: MFCD03792786
Linear Formula: C20H21N4O2F
Product Type: Chemical
| assay | >98% (HPLC) |
| color | white |
| form | powder |
| InChI | 1S/C20H21FN4O2/c1-27-20-2 |
| InChI key | ZQUSFAUAYSEREK-WKILWMFISA |
| mp | 206-207.2 °C |
| originator | GlaxoSmithKline |
| Quality Level | 100 ![]() |
| SMILES string | COc1nccc(n1)-c2c(ncn2[C@@ |
| solubility | DMSO: 11 mg/mL |
| H2O: insoluble | |
| storage temp. | 2-8°C |
| Application: | SB 239063 has been used to determine the roles of c-Jun N-terminal kinase (JNK), p38 MAP kinase, and extracellular signal regulated protein kinase (ERK)/p42/p44 mitogen activated protein kinase (MAPK) on the viability and apoptosis of cardiomyocytes under glutathione S-transferase (GST) inhibition. It has also been used in neuron-microglia conditioned media (CM) experiments and pharmacokinetics. |
| Biochem/physiol Actions: | Potent p38 MAP kinase inhibitor. Selective for α and β. No activity against γ and δ isoforms. |
| Features and Benefits: | This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| General description: | SB 239063 helps to decrease neutrophilia, inflammatory cytokines, matrix metallopeptidase 9 (MMP-9) and fibrosis in the lung. |
| Legal Information: | Sold for research purposes under agreement from GlaxoSmithKline |
| Packaging: | 5, 25 mg in glass bottle |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | >98% (HPLC) |
| mp | 206-207.2 °C |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |

